Abemaciclib, aromatase inhibitor, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with ..
Lancet, Mekinist, Tamoxifen, Trametinib
New treatment identified for low grade and serous ovarian cancer
May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy an..
Abemaciclib, Agilent, Dako Omnis, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib is approved by FDA with endocrine therapy for early breast cancer
October 2021: The Food and Drug Administration has approved abemaciclib (Verzenio, Eli Lilly and Company) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with ho..